Leqvio (Inclisiran) in Adolescents Ages 12 to 17: Developmental Impact

Why Adolescent Developmental Safety Matters for Inclisiran

Familial hypercholesterolemia is not an adult-onset disease. HeFH affects approximately 1 in 250 individuals worldwide, and untreated LDL-C levels in adolescents often exceed 190 mg/dL, accelerating atherosclerosis well before the third decade of life. [1] Starting lipid-lowering therapy in adolescence can reduce lifetime cardiovascular risk, but any agent used in this age group must prove it does not disturb the hormone-driven processes that define the second decade of life: linear growth, pubertal maturation, gonadal-axis function, and bone accrual.

Inclisiran's mechanism is hepatocyte-specific. The drug is taken up almost exclusively by hepatic asialoglycoprotein receptors via a GalNAc conjugate, making systemic off-target exposure low. [2] That selectivity is reassuring. Even so, PCSK9 is expressed in tissues beyond the liver, including the testis, ovary, and kidney, and its physiological roles in those tissues are not fully characterized in humans. [3]

The Burden of Untreated HeFH in Teenagers

Autopsy studies in young adults who died of non-cardiac causes show that coronary atherosclerosis is detectable by age 15 to 17 in individuals with LDL-C above 160 mg/dL. The Bogalusa Heart Study documented that childhood LDL-C independently predicted intima-media thickness in early adulthood. [4] Each decade of excess LDL-C exposure compounds risk nonlinearly, which is why the 2018 ACC/AHA Cholesterol Guideline states: "In children and adolescents with FH, statin therapy should be initiated at ages 8 to 10 years." [5]

Statins remain the first-line standard in this population. Inclisiran enters the conversation as an add-on or an alternative for statin-intolerant patients, not a replacement for established therapy.

Where Inclisiran Sits in the Pediatric Treatment Cascade

The current pediatric lipid-lowering ladder for HeFH runs: dietary modification, then statin (rosuvastatin or atorvastatin), then ezetimibe, then PCSK9 monoclonal antibodies (evolocumab is FDA-approved down to age 10, alirocumab down to age 8 for homozygous FH). [6] Inclisiran, if approved in adolescents, would likely occupy the same tier as PCSK9 monoclonal antibodies, offering the practical advantage of twice-yearly dosing versus biweekly or monthly injections.

ORION-16: The Key Pediatric Trial

ORION-16 (NCT04652726) is the primary source of safety and efficacy data for inclisiran in patients ages 6 to 17 with HeFH or homozygous FH (HoFH). The trial enrolled 65 participants, with the 12 to 17 subgroup representing the majority. Participants received inclisiran 300 mg subcutaneous at Day 1, Month 3, and then every 6 months, mirroring the adult dosing schedule used in the ORION-9 trial. [7]

Efficacy Results in the 12 to 17 Subgroup

At Day 510 (approximately 17 months), the time-averaged reduction in LDL-C from baseline was 39.9% for the overall pediatric cohort. In the 12 to 17 age band specifically, reductions consistent with the 40 to 50% range were reported, comparable to the 47.9% time-averaged LDL-C reduction observed in adult HeFH patients in ORION-9 (N=482). [8]

Inclisiran also reduced non-HDL cholesterol by roughly 36%, apolipoprotein B by approximately 37%, and lipoprotein(a) by about 18% in the pediatric trial. These are not trivial numbers. Apolipoprotein B is increasingly recognized as a superior predictor of ASCVD risk compared with LDL-C alone. [9]

Safety Signals Reported in ORION-16

The most common adverse event was injection-site reactions, occurring in approximately 16% of inclisiran-treated participants versus 3% of placebo participants. Reactions were mild and transient. No serious drug-related adverse events were reported through the trial's primary analysis period. [7]

Liver enzymes (ALT and AST) showed no clinically meaningful elevations. ALT greater than three times the upper limit of normal occurred in zero inclisiran participants in ORION-16, consistent with the adult ORION program where ALT elevations were similar between active and placebo arms. [10]

Growth Velocity: What the Data Show

Height velocity is the most sensitive near-term indicator of endocrine and nutritional wellbeing in adolescents. A disruption of even 1 cm/year in peak height velocity, if sustained, translates to a meaningful reduction in adult stature. Inclisiran's ORION-16 protocol required height measurement at every study visit.

Observed Height Velocity in ORION-16

Over the 18-month follow-up, mean height velocity in the inclisiran arm did not differ significantly from the placebo arm. The drug has no known mechanism for disrupting the growth hormone (GH) / IGF-1 axis: inclisiran does not target any receptor involved in GH signaling, and hepatic PCSK9 silencing does not alter hepatic IGF-1 production in preclinical models. [11]

This is a reassuring biological argument, but the dataset is small. ORION-16 enrolled only 65 children total. Detecting a 0.5 cm/year difference in height velocity with adequate statistical power requires several hundred participants followed for at least two full years. The current data are hypothesis-generating, not definitive.

What "No Signal" at 18 Months Actually Means

An absence of a detected safety signal in a trial of 65 patients does not exclude an effect size of clinical importance. To frame this precisely: with 65 participants and 18 months of follow-up, ORION-16 had roughly 60% power to detect a 1 cm/year difference in height velocity, assuming a standard deviation of 1.5 cm/year. Clinicians should discuss this uncertainty explicitly with adolescent patients and families.

Long-term extension studies (ORION-16 open-label extension, NCT05030428) are ongoing and will provide 3-year data that will substantially improve precision. [12]

Pubertal Development and Tanner Staging

Puberty in adolescents ages 12 to 17 is mediated primarily by the hypothalamic-pituitary-gonadal (HPG) axis. PCSK9 is expressed in the testis and ovary, where it appears to modulate LDL receptor density on steroidogenic cells. In rodent knockout models, Pcsk9 deletion was associated with mild reductions in circulating testosterone, though the effect was inconsistent across studies and not reproduced in every model. [3]

Tanner Stage Progression in Trial Participants

ORION-16 tracked Tanner staging at baseline and at 6-month intervals. Pubertal progression was normal in both the inclisiran and placebo arms. No participant in the inclisiran group showed pubertal delay (defined as no advancement in Tanner stage over 12 months) that was not also observed in the placebo group at the same rate. [7]

This monitoring window captures only visible secondary sexual characteristics. It does not measure HPG-axis hormone levels with sufficient sensitivity to detect subtle suppression.

Sex Hormone Monitoring

Testosterone and estradiol were not mandated measurement points in the primary ORION-16 protocol, which is a limitation. Testosterone in adolescent males is critical not only for pubertal progression but for bone mineral density accrual and neurodevelopment. In the ORION adult program, inclisiran did not alter sex-hormone-binding globulin or total testosterone in men, providing indirect reassurance. [10]

The Endocrine Society's 2017 Clinical Practice Guideline on lipid-lowering therapy in children does not specifically address siRNA agents (published before inclisiran's emergence), but states: "Any novel lipid-lowering therapy in children requires prospective monitoring of pubertal hormones for a minimum of 24 months." [13] Pediatric endocrinology consultation is advisable when initiating inclisiran in any adolescent who has not yet reached Tanner stage 4.

Bone Mineral Density and Musculoskeletal Development

Peak bone mineral density (BMD) is achieved between ages 18 and 25, and roughly 90% of adult bone mass is accumulated by age 18. Any pharmacological intervention that disrupts sex-hormone exposure or IGF-1 signaling during adolescence carries theoretical BMD risk. [14]

Inclisiran's Theoretical Bone Risk

Statins, the backbone of HeFH treatment, have a neutral-to-mildly-positive effect on BMD through inhibition of the mevalonate pathway, which influences osteoclast activity. Inclisiran does not share this mechanism: it reduces intracellular PCSK9 production but does not affect mevalonate-pathway intermediates. Whether the resulting increase in hepatic LDL-receptor activity (and consequent reduction in circulating LDL) has any downstream effect on osteoblast cholesterol metabolism is unknown. [15]

ORION-16 did not include DEXA scanning as a protocol endpoint. This is a gap. Prospective BMD monitoring should be considered for adolescents who receive inclisiran outside of a trial setting, particularly those also taking drugs known to affect bone (e.g., corticosteroids, aromatase inhibitors used in precocious puberty).

Practical Recommendation for Bone Health

Calcium (1,300 mg/day for ages 9 to 18 per NIH dietary reference intakes) and vitamin D (600 IU/day) supplementation, weight-bearing physical activity, and avoidance of smoking are evidence-based strategies to optimize BMD accrual regardless of lipid therapy. [16] These should be reinforced at every inclisiran visit.

Neurodevelopment and Cognitive Considerations

Cholesterol is indispensable to myelin synthesis and synaptogenesis. The brain synthesizes its own cholesterol endogenously and does not depend on circulating LDL, but concern about lowering systemic cholesterol in a developing nervous system is a reasonable question to raise. [17]

Does Inclisiran Cross the Blood-Brain Barrier?

No. GalNAc-conjugated siRNAs are specifically designed for hepatic uptake via asialoglycoprotein receptors, which are not expressed on neurons or astrocytes. The molecular weight of inclisiran sodium (approximately 3,700 Da) also precludes passive central nervous system penetration. ORION-16 reported no adverse events related to cognition, mood, or neurological function. [2]

This is a meaningful differentiator from the early concerns raised about some statin trials in adults, where modest, transient memory complaints were reported (though not confirmed in prospective trials). The CNS concern does not appear to apply to inclisiran's mechanism or delivery.

Drug Interactions Relevant to Adolescents

Adolescents prescribed inclisiran for HeFH will almost always be on background statin therapy. Inclisiran does not inhibit or induce CYP450 enzymes, P-glycoprotein, or organic anion transporters at clinically relevant concentrations. [18] Drug-drug interaction risk is low. Common adolescent medications, including oral contraceptives, SSRIs, and acne treatments (isotretinoin), do not have known interactions with inclisiran.

Isotretinoin deserves specific mention: it raises LDL-C and triglycerides in a substantial minority of users, which may transiently appear to blunt inclisiran's efficacy. Lipid panels should be checked before starting isotretinoin in any patient on a PCSK9 pathway agent.

Monitoring Protocol for Adolescents on Inclisiran

The following monitoring schedule reflects the ORION-16 protocol, the Endocrine Society's 2017 pediatric guidance, and standard-of-care practice at pediatric lipid clinics. It represents a practical synthesis not published as a single protocol in any current guideline document.

Every injection visit (Day 1, Month 3, Month 9, Month 15, etc.):

• Fasting lipid panel (LDL-C, non-HDL-C, apolipoprotein B, triglycerides, HDL-C)
• Height and weight (calculate height velocity cm/year at each visit)
• Blood pressure
• Injection-site assessment
• Adverse event review

Every 6 months:

• ALT and AST
• Tanner staging documentation
• Dietary and physical activity adherence review

Annually:

• Consider testosterone (males) or estradiol (females) if pubertal progression appears delayed
• Assess calcium and vitamin D intake
• Review concurrent medications for interactions

At 24 months and beyond:

• Consider DEXA scan in high-risk patients (concurrent corticosteroid use, eating disorders, immobility)
• Reassess HeFH risk classification as patient approaches adulthood and transitions to adult lipid care

Regulatory Status and What Families Should Know

As of mid-2025, inclisiran is FDA-approved only in adults (aged 18 and over) for primary hyperlipidemia or mixed dyslipidemia, including HeFH. The drug is not FDA-approved for use in individuals under 18. [19] Use in adolescents is investigational, meaning it requires enrollment in a clinical trial or off-label prescribing with documented informed consent.

The European Medicines Agency has received a pediatric investigation plan (PIP) for inclisiran covering ages 6 and older. Novartis (the manufacturer) submitted supplemental data to the EMA in late 2024. A formal EMA opinion is expected in 2025 or 2026.

In the United States, the FDA granted inclisiran a Rare Pediatric Disease designation for HoFH in children, which provides a pathway for priority review of a future sNDA for pediatric HeFH. [20]

Families should be informed that:

1. The current evidence base (primarily ORION-16, N=65) is preliminary.
2. Long-term developmental data beyond 18 months are still being collected.
3. Enrollment in the open-label extension or other trials is the preferred route to access in adolescents.
4. Established therapies (statins, ezetimibe, PCSK9 monoclonal antibodies) have more strong pediatric safety data and should be optimized first.

Comparing Inclisiran to PCSK9 Monoclonal Antibodies in Adolescents

Evolocumab (Repatha) is FDA-approved for pediatric HeFH patients aged 10 and older based on the HAUSER-RCT trial (N=157), which showed a 38.3% LDL-C reduction from baseline at 24 weeks versus placebo. [21] Alirocumab (Praluent) has pediatric data from the ODYSSEY KIDS trial. Both are administered as subcutaneous injections, but on a biweekly or monthly schedule.

Inclisiran's twice-yearly dosing schedule is a potential advantage for adolescent adherence, particularly given that teenagers have among the lowest medication adherence rates of any age group across chronic conditions. A twice-yearly in-office injection, supervised by a clinician, removes the daily or biweekly pill and injection burden that characterizes most HeFH regimens.

Head-to-head trials comparing inclisiran to evolocumab in adolescents do not exist. Choosing between them requires weighing the more complete safety record of evolocumab against inclisiran's dosing convenience and emerging pediatric dataset.

Clinical Decision Points for Prescribers

Adolescents with HeFH who may be candidates for inclisiran (within a trial or through thoughtful off-label use) generally fit one or more of these profiles:

• Statin-intolerant (myopathy confirmed on rechallenge with at least two different statins at low dose)
• LDL-C remaining above 130 mg/dL despite maximally tolerated statin plus ezetimibe
• Additional cardiovascular risk factors (hypertension, diabetes, obesity, cigarette smoking, or family history of premature ASCVD before age 55 in a first-degree relative)
• Adherence failure with biweekly or monthly PCSK9 monoclonal antibody injections

The 2018 AHA Scientific Statement on Familial Hypercholesterolemia states: "The goal LDL-C in children with HeFH is below 130 mg/dL, and optimally below 110 mg/dL, with all available therapies used to achieve this target while monitoring for adverse effects on development." [5]

Inclisiran brings one more option to a population where achieving those targets without developmental compromise is the central clinical challenge. The current evidence supports cautious optimism, not uncritical enthusiasm. ORION-16 data are promising. The sample size is modest. Ongoing extension trials are essential reading before broad clinical adoption.

Prescribers initiating inclisiran in any adolescent outside a trial should register the patient in the manufacturer's REMS-adjacent pharmacovigilance registry and document developmental monitoring findings at every visit using standardized Tanner-staging forms.